Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)

NCT06005259 is registered in ClinicalTrials.gov with University of Sao Paulo as lead sponsor.

NCT NCT06005259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06005259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity: a Randomized Clinical Trial (SPIROTOX Trial)
Lead sponsor
University of Sao Paulo
Phase
Phase 4
Overall status
Unknown status
Start date
October 1, 2023
Completion date
December 1, 2025
Enrollment
264 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity, chemotherapy effect, heart failure, neoplasms